Protagenic (PTIX) Exec Chair Armen Garo H Buys 20,000 Shares

What Happened
Armen Garo H, Executive Chair, Principal Officer and Director of Protagenic Therapeutics, bought 20,000 shares of PTIX in an open-market purchase on August 21, 2026. The shares were acquired at $0.65 per share for a total transaction value of $13,000. This was a direct purchase (transaction code P), which is an insider acquisition rather than a sale.

Key Details

• Transaction date: 2026-08-21; Filed with SEC: 2026-08-24 (Form 4 accession 0001493152-26-039816)
• Price per share: $0.65; Shares acquired: 20,000; Total value: $13,000
• Shares owned after transaction: Not specified in the provided filing details
• Notable footnotes/plans: No 10b5-1 plan, tax withholding, or other special notations reported in the provided data
• Filing timeliness: The Form 4 was filed three days after the transaction date; the filing itself does not indicate a tardiness notation in the provided summary

Context
This was a straightforward open-market purchase (code P), not an option exercise, gift, or award. Insider purchases can be interpreted by investors as a sign of confidence, but this was a relatively small-dollar transaction ($13k) and should be weighed along with other filings and company fundamentals.